Court rules Johnson & Johnson defrauded State of Louisiana in marketing Risperdal

On October 13, a jury in Louisiana returned a verdict that Johnson & Johnson had defrauded the State in marketing the anti-psychotic Risperdal, and entered a verdict against the company in the amount of 257 million dollars.  The jury found more than 35,000 violations of the Medical Assistance Programs Integrity Law, and held that the company had misled doctors about the risks and benefits of the medicine.